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In brain cortex, low concentrations of GTP or Gpp(NH)p activated the membrane-bound low K,,, cyclic 
AMP phosphodiesterase while higher concentrations of GTP, but not of Gpp(NH)p, reversed this 
activation. The adenosine analog N6-phenylisopropyladenosine (@-PIA) elicited biphasic effect on this 
enzyme (activation up to 10d8 M, complete reversion at lo-’ M), provided that GTP was present. N6-PIA 
activation was reduced in the presence of Gpp(NH)p and blocked by sodium (80 mM). In contrast, the 
soluble low K,,, cyclic AMP phosphodiesterase was insensitive to GTP or N6-PIA. This study suggests that 
guanine nucleotides and @-PIA exert their effects on the membrane-bound enzyme through guanine 
nucleotide regulatory proteins. 
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Guanine nucleotide regulatory protein Brain cortex 
1. INTRODUCTION 
Previous studies from this laboratory [l] have 
shown that adrenalectomy results in an impaired 
reactivity of the adenylate cyclase-phosphodiester- 
ase system in response to the ‘R’ adenosine site 
agonist, N6-phenylisopropyladenosine (Z@-PIA), 
in rat white fat cells. In normal brain, a tissue 
sharing common properties with the adipocyte, at 
least with regard to the coexistence of ‘Ri’ and ‘Ra’ 
adenosine sites (review [2]), we have recently pro- 
vided evidence suggesting that in the presence of 
the guanine nucleotide GTP, @-PIA may stimu- 
late the low K, cyclic AMP phosphodiesterase [3]. 
Furthermore, in the same study we also found that 
N6-PIA inhibited this enzyme after adrenalectomy. 
The aim of the present work was to clarify the 
role played by GTP in both the regulation of the 
* To whom correspondence should be addressed 
brain low K,,, cyclic AMP phosphodiesterase and in 
the effects of A@-PIA on this enzyme. 
Furthermore, as low K,,, cyclic AMP phospho- 
diesterase activity has been detected in both the 
membranes and the cytosol of several tissues [4,5] 
including the brain [6], we have focused this study 
on these two forms of this enzyme. 
2. MATERIALS AND METHODS 
[3H]Cyclic AMP (36 Ci/mmol) was from the 
Radiochemical Centre Amersham, N6-PIA, 
adenosine deaminase, cyclic AMP, Gpp(NH)p and 
GTP from Boehringer. The phosphodiesterase in- 
hibitor Ro-1724 was kindly supplied by Hoffman- 
La Roche. 
. 
Brain cortical membrane and cytosolic fractions 
were prepared from Wistar male rats (150 g) as 
follows. Cortex from freshly decapitated rats were 
sliced and incubated at 37°C for 30 min in Krebs- 
Ringer phosphate buffer. The brain slices were 
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then transferred to ice-cold Tris-HCl buffer 
(50 mM, pH 7.4), homogenized and centrifuged at 
800 x g for 5 min at 4°C. The pellet was discarded 
and the supernatant centrifuged at 3000 x g for 
10 min at 4°C. The resulting supernatant and 
pellet were separated and recentrifuged at 48 000 x 
g for 30 min at 4°C. The pellet issued from the 
centrifugation of the 3000 x g pellet was used to in- 
vestigate the ‘membrane-bound’ low K, cyclic 
AMP phosphodiesterase activity, while the super- 
natant issued from the centrifugation of the 
3000 x g supernatant served as the source of the 
soluble form of this enzymic activity. 
The low K, cyclic AMP phosphodiesterase ac- 
tivity was assayed by a slight modification of the 
method in [3]. Incubations were performed in a 
final volume of 600~1 containing 0.02 ,uM 
[3H]cyclic AMP, 0.08 pM cyclic AMP, 30 mM 
Tris-HCl buffer (pH 7.4), 5 mM MgC12, 0.04% 
bovine serum albumin, 0.25 units/ml adenosine 
deaminase and, when indicated, GTP or 
Gpp(NH)p at various concentrations. Reactions 
were initiated by the introduction of 20-50 pg pro- 
tein and, after 5 min of incubation at 25”C, reac- 
tions were stopped by boiling the tubes for 90 s 
after which low K,,, cyclic AMP phosphodiesterase 
activities were determined as in [3]. Conversion of 
cyclic AMP into products was not allowed to ex- 
ceed 15% over the incubation period time (5 min 
at 25°C) and was linear during this time and with 
protein (up to 1OOpg protein). 
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Fig. 1. Dose-response curves to GTP and Gpp(NH)p of 
the membrane-bound and soluble low K,,, cyclic AMP 
phosphodiesterase in rat brain cortex. Data are 
expressed as percentage over basal activity and represent 
the mean values of 3-5 separate xperiments performed 
in triplicate which differed by less than 5%. (0) 
Membrane-bound phosphodiesterase with GTP, (0) 
membrane-bound phosphodiesterase with Gpp(NH)p, 
(A) soluble phosphodiesterase with GTP. Mean + SE 
control activities (no addition) were 57 * 5 
pm01~mg-‘~min-’ for the membrane-bound (  = 8) and 
115 + 17 pmol * mg-’ emin-’ for the soluble phospho- 
3. RESULTS AND DISCUSSION 
To avoid the interference of the high Km 
phosphodiesterase activities, kinetic studies of the 
soluble and membrane-bound low K,,, phospho- 
diesterase activities were first performed with sub- 
strate concentrations ranging from 0.1 to 5 pM. 
Under these conditions, the Km values found for 
the soluble and membrane-bound enzymes were 
1.5 f 0.1 and 1.0 f 0.2 PM (n = 3), respectively, 
which are in good agreement with those reported in 
171. 
higher concentrations, a progressive reversal of 
this activation (the activity is brought back to the 
basal level at 1 PM GTP). Kinetic studies revealed 
that the time-course of the GTP (30 nM) ac- 
tivatory effect was rapid, equilibrium being reach- 
ed within the first min of incubation (not shown). 
Furthermore, this effect was reversible. In fact, ex- 
periments in which the membrane-bound fraction 
was preincubated in the substrate-free phospho- 
diesterase assay medium without (control) or with 
30 nM GTP for 5 min, washed twice and then 
tested for phosphodiesterase activity, showed no 
difference between the control and the GTP-ex- 
posed fractions (not shown). 
From fig. 1, it is clear that the soluble 
phosphodiesterase is insensitive to the addition of 
GTP in the incubation medium. On the contrary, 
the membrane-bound activity was sensitive to 
GTP, showing a biphasic response with, at GTP 
concentrations up to 30 nM, an activation and, at 
Since cyclic GMP has been shown to be an ac- 
tivator of the phosphodiesterase particulate form 
[8], it could not be excluded that the activation by 
GTP of the membrane-bound enzyme could be ar- 
tifactually due to the presence of cyclic GMP 
generated from GTP by guanylate cyclase. This 
possibility seems, however, unlikely for the follow- 
February 1984 
diesterase (n = 4). 
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ing reasons. First, half-maximal activation of the 
phosphodiesterase by cyclic GMP occurs in the 
10pM range [8] which ,is at least 3 orders of 
magnitude higher than the GTP concentrations 
eliciting half-maximal activation of the enzyme. 
Second, as seen in fig.1, the non-hydrolysable 
GTP analog, Gpp(NH)p, also activated the 
membrane-bound phosphodiesterase, a result 
which is uncompatible with a cyclic GMP- 
dependent process and which furthermore rules 
out the possibility that a direct phosphorylation of 
the enzyme by GTP may be involved in this pro- 
cess. Although low concentrations of both GTP 
and Gpp(NH)p activated the membrane-bound 
phosphodiesterase, concentrations of Gpp(NH)p 
above lOa M did not lead, contrary to GTP, to a 
reversion of the activation process (fig.1). This 
suggests that GTP hydrolysis is probably required 
for the expression of the GTP inhibitory process. 
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The bimodal action of GTP on the membrane- 
bound phosphodiesterase r ported here is intrigu- 
ing considering the analogies existing between this 
action and the well established bimodal regulation 
of adenylate cyclase systems by guanine 
nucleotides (review [9]). In fact the data in fig. 1 are 
compatible with the existence of two different 
GTP-dependent regulatory sites for phospho- 
diesterase, one displaying high affinity for GTP 
and mediating activation of the membrane-bound 
enzyme and the other one having lower affinity 
and inhibiting the enzyme only when GTP is 
hydrolyzed. It is thus tempting to postulate that 
the membrane-bound phosphodiesterase is 
positively and negatively coupled to two different 
guanine-nucleotide regulatory proteins resembling 
the ‘Ni’ and ‘Ns’ proteins involved in adenylate 
cyclase coupling processes [9]. 
Fig.2. Dose-response curves to N6-phenylisopropylade- 
nosine of the membrane-bound and soluble low K,,, 
cyclic AMP phosphodiesterase in rat brain cortex. 
Values are expressed as in fig.2 and are the mean values 
of 3-5 separate experiments performed in triplicate. (A) 
Membrane-bound enzyme without guanine nucleotides, 
(0) membrane-bound enzyme with GTP (10e8 M), (0) 
membrane-bound enzyme with GTP (10m5 M), (0) 
membrane-bound enzyme with Gpp(NH)p (lo-’ M), ( l )
membrane-bound enzyme with GTP (10v5 M) and Na+ 
(80 mM), (A) soluble enzyme with GTP (lo-* M). 
the enzyme (ECHO = 0.015 nM, maximal effect 
+ 45%), whereas higher concentrations tended to 
reverse this response (EC50 = 15 nM). Like the 
GTP-activatory effect described above, the time- 
course of the phosphodiesterase stimulation in- 
duced by 0.3 nM N6-PIA was rapid (equilibrium 
being reached in less than 1 min) and was rever- 
sible (not shown). 
To test this hypothesis, the possibility was in- Surprisingly, addition of 80 mM sodium 
vestigated that the membrane-bound phospho- abolished the activatory and inhibitory effects of 
diesterase might be biphasically modulated by the @-PIA (fig.2). As already mentioned, these two 
adenosine analog N6-PIA which, through binding effects were strictly dependent on the presence of 
to Ri or Ra sites, exerts a GTP-dependent adenyl- high GTP concentrations, since, as shown in fig.2, 
ate cyclase inhibition or activation (review [2]). As the membrane-bound enzyme became unrespon- 
shown in fig.2, while the soluble enzyme was insen- sive to N6-PIA when studied in the absence or in 
sitive to N6-PIA (whether GTP was present or the presence of lo-* M GTP. As also shown, 
not), the membrane-bound enzyme elicited a degrees of activation and inhibition by N6-PIA 
biphasic response to N6-PIA provided that high were half-reduced when GTP was replaced by 
concentrations (10m5 M) of GTP were present in 10m5 M Gpp(NH)p. As this unexpected finding 
the assay. Under these conditions, extremely low was observed at all N6-PIA concentrations tested, 
N6-PIA concentrations (up to 0.3 nM) stimulated it cannot be explained by the reduced binding af- 
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finity of the Ri sites for adenosine agonists which 
is induced by Gpp(NH)p [lo]. Moreover, this fin- 
ding also excludes the possibility that the 
phosphodiesterase activation due to N6-PIA in- 
volves either a GTP-mediated phosphorylation of 
the enzyme or, because these experiments were per- 
formed in the absence of ATP, enzyme 
phosphorylation mediated by ATP. Thus, the 
mechanism through which N6-PIA modulates the 
membrane phosphodiesterase in the brain appears 
different from the ATP-dependent phosphoryla- 
tion mechanism which has been recently proposed 
[l l] to explain the insulin-stimulation of 
phosphodiesterase in liver plasma membranes. 
From these results, there are some arguments 
suggesting that both the activatory and inhibitory 
effects of @-PIA on the membrane-bound 
phosphodiesterase might be mediated through the 
adenylate cyclase negatively and positively coupled 
Ri and Ra sites, respectively. In fact: 
(i) the time-course of occurrence of these two ef- 
fects was rapid (in the min range); 
(ii) the N6-PIA concentrations eliciting phospho- 
diesterase activation and inhibition were com- 
patible with the N6-PIA concentrations re- 
quired to observe N6-PIA binding to the Ri 
and Ra sites respectively [2]; 
(iii) like the Ri and Ra site-mediated effects of 
@-PIA on adenylate cyclase [9], activation 
and inhibition of phosphodiesterase by 
A@-PIA required GTP; 
(iv) finally, only the membrane-bound enzyme 
was found sensitive to both effects of @-PIA. 
Whether the GTP-dependent N6-PIA effects on 
phosphodiesterase are mediated or not by GTP- 
binding proteins remains an open question. Sup- 
porting such a mediation are several recent reports 
[12-141 concerning other GTP-dependent 
membrane-bound phosphodiesterases: the insulin- 
stimulated cyclic AMP phosphodiesterase of the 
liver [9] or the photolyzed activated cyclic GMP 
phosphodiesterase of the rod outer segments 
[13-161 which depends on transducin, a GTP- 
dependent protein structurally similar [ 171 but 
functionally different from the Ni and Ns proteins 
involved in adenylate cyclase regulation [18-201. 
The same situation may also apply to the N6-PIA 
effects on the membrane-bound cyclic AMP 
phosphodiesterase of the brain since: 
(i) Gpp(NH)p which prevents the Ni-mediated in- 
hibitory effect of @-PIA on adenylate cyclase 
[12], reduced but did not abolish the N6-PIA- 
induced phosphodiesterase stimulation; 
(ii) sodium ions, which promote the Ni-mediated 
inhibition of adenylate cyclase by @-PIA [ 181 
without affecting the Ns-mediated adenylate 
cyclase activation [9], suppressed both the 
N6-PIA-induced phosphodiesterase activation 
and inhibition. 
Further studies using toxins which specifically 
alter Ns [19] or Ni [20-221 would be helpful to 
elucidate the nature of the factors mediating the 
N6-PIA effects reported here. 
Finally, this study suggests an important role for 
adenosine in the control of cyclic AMP meta- 
bolism in the brain cortex. In fact, N6-PIA, at least 
at low concentrations, contributes to decrease 
cyclic AMP levels not only because it is a well 
known inhibitor of adenylate cyclase [23], but 
also, as shown here, because it stimulates cyclic 
AMP phosphodiesterase. As the latter effect is also 
induced by insulin [5-241, the presently reported 
phosphodiesterase stimulation by N6-PIA con- 
stitutes an additional example of an insulin-like ac- 
tion of adenosine [25]. 
ACKNOWLEDGEMENTS 
We are grateful to Mrs Brigitte Agli for expert 
technical assistance and to Miss Brigitte Vincent 
for the preparation of this manuscript. This work 
was supported by the INSERM (grant CRL 824 
005) and by the Direction de la Recherche (Univer- 
sitC RenC Descartes, Paris V). 
REFERENCES 
[II 
t21 
131 
[41 
PI 
De Mazancourt, P., Thotakura, H. and Giudicelli, 
Y. (1982) Biochem. Biophys. Res. Commun. 3, 
987-994. 
Wolff, J., Londos, C. and Cooper, D.M.F. (1981) 
Adv. Cyclic Nucl. Res. 14, 199-215. 
De Mazancourt, P. and Giudicelli, Y. (1984) Brain 
Res., in press. 
Makino, H., De Buschiazzo, P.M., Pointer, R.H., 
Jordan, J.F. and Kono, I. (1980) J. Biol. Chem. 
255, 1845-7849. 
Loten, E.G., Assimacopoulos-Jeannet, F.D., 
Exton, J.H. and Park, C.R. (1978) J. Biol. Chem. 
253, 746-757. 
145 
Volume 167, number 1 FEBSLETTERS February 1984 
[6] Beavo, J .A., Hardman, J .G. and Sutherland, E .W. 
(1970) J. Biol. Chem. 245, 5649-5655. 
[7] Appleman, M.M., Thompson, W.J. and Russel, 
T.R. (1973) Adv. Cyclic Nucl. Res. 3, 65-98. 
[8] Beavo, J.A., Hardman, J.G. and Sutherland, E.W. 
(1971) J. Biol. Chem. 246, 3841-3846. 
[9] Cooper, D.M.F. (1982) FEBS Lett. 138, 157-163. 
[lo] Goodman, R.R., Cooper, M.J., Gavish, M. and 
Snyder, S.H. (1982) Mol. Pharmacol. 21,329-335. 
[ll] Marchmont, R.J. and Houslay, M.D. (1980) 
Nature 286, 904-906. 
[12] Heyworth, C.M., Rawal, S.R. and Houslay, M.D. 
(1983) FEBS Lett. 154, 87-91. 
1131 Miki, N., Baraban, J.M., Keirns, J. J., Boyle, J. J. 
and Bitensky, M.W. (1975) J. Biol. Chem. 250, 
6320-6327. 
[14] Wheeler, G.L. and Bitensky, M.W. (1977) Proc. 
Natl. Acad. Sci. USA 74, 4238-4242. 
(151 Fung, B.K.K. and Stryer, L. (1980) Proc. Natl. 
Acad. Sci. USA 77, 2500-2504. 
[Ia] Kohnken, R.E., Eadie, D.M. and McConnell, 
D.G. (1981) J. Biol. Chem. 256, 12510-12516. 
[17] Manning, D.R. and Gilman, A.G. (1983) J. Biol. 
Chem. 258, 7059-7063. 
[18] Aktories, K., Schultz, G. and Jakobs, K.H. (1981) 
Eur. J. Pharmacol. 71, 157-160. 
[19] Sternweis, P.C., Northup, J.K., Hanski, E., 
Schleifer, L.S., Smigel, M.D. and Gilman, A.G. 
(1981) Adv. Cyclic Nucl. Res. 14, 23-36. 
[20] Katada, T. and Ui, M. (1982) Proc. Natl. Acad. 
Sci. USA 79, 3129-3133. 
[21] Katada, T. and Ui, M. (1982) J. Biol. Chem. 257, 
7210-7216. 
[22] Hildebrandt, J.D., Sekura, R.D., Codina, J., 
Iyengar, R., Manclark, C.R. and Birnbaumer 
(1983) Nature 302, 706-708. 
1231 Cooper, D.M.F., Londos, C. and Rodbell, M. 
(1980) Mol. Pharmacol. 18, 598-601. 
[24] Manganiello, V. and Vaughan, M. (1973) J. Biol. 
Chem. 248, 7164-7170. 
[25] Solomon, S.S., Turpin, B.P. and Duckworth, 
W.C. (1980) Horm. Metab. Res. 12, 601-604. 
146 
